Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2020 Apr 18;108(1):93–103. doi: 10.1016/j.ijrobp.2020.04.013

Figure 5.

Figure 5.

Progression (combined regional and distant) free survival for 59 warfarin users and 397 non-warfarin users with cT1–2N0 non-small cell lung cancers treated with stereotactic body radiotherapy (SABR) for curative intent at two different institutions.